These clinical observations suggest that high expression of CLK2 and MYC amplification worsen the prognosis of particular subtypes of breast cancer patients and that CLK inhibitor would be more effective to these poor prognosis cancers. The gene discussed is MYC; the disease is breast carcinoma.